

## 5. LITERATUR

---

### Zeitschriftenartikel:

1. Armstrong VW, Shipkova M, Schütz E, Weber L, Tönshoff B, Oellerich M for the German Study Group On MMF Therapie In Pediatric Renal Transplant Recipients (2001): Monitoring of mycophenolic acid in pediatric renal transplant recipients. *Transplant Proc* 33: 1040-1043
2. Barone GW, Gurley BJ, Ketel BL, Abul-Ezz SR (2001): Herbal supplements: A potential for drug interactions in transplant recipients. *Transplantation* 71 (2): 239-241
3. Bays HE, Dujovne CA (1998): Drug interactions of lipid-altering drugs. *Drug Saf* 19 (5): 355-371
4. Belitsky P (2000): Neoral<sup>®</sup> use in the renal transplant recipient. *Transplant Proc* 32 (3A): 10S-19S
5. Bistrup C, Nielsen FT, Jeppesen UE, Dieperink H (2001): Effect of grapefruit juice on Sandimmun Neoral<sup>®</sup> absorption among stable renal allograft recipients. *Nephrol Dial Transplant* 16: 373-377
6. Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant S, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E (1999): A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. *Am J Kidney Dis* 33: 694-701
7. Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998): Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. *Am J Kidney Dis* 31: 607-617
8. Bökenkamp A, Offner G, Hoyer PF, Vester U, Wonigeit K, Brodehl J (1995): Improved absorption of Cyclosporin A from a new microemulsion formulation: Implications for dosage and monitoring. *Pediatr Nephrol* 9: 196-198
9. Braunlin W, Zhorov E, Guo A, Apruzzese W, Xu Q, Hook P, Smisek DL, Mandeville WH, Holmes-Farley SR (2002): Bile acid binding to sevelamer HCL. *Kidney Int* 62: 611-619
10. Brunet M, Martorell J, Vilardell J, Millán O, Carrillo M, Rojo I, Corbella J (2000): Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal

- transplant recipients treated with low doses of mycophenolate mofetil. *Transpl Int* 13 (1): S301-S305
11. Brunner LJ, Pai K-S, Munar MY, Lande MB, Olyaei AJ, Mowry JA (2000): Effect of grapefruit juice on cyclosporin A pharmacokinetics in pediatric renal transplant patients. *Pediatr Transplant* 4: 313-321
  12. Budde K, Glander P, Braun KP, Böhler T, Waiser J, Fritsche L, Mai I, Neumayer H-H (2001): Pharmacodynamic monitoring of mycophenolate mofetil in renal allograft recipients. *Transplant Proc* 33: 3313-3315
  13. Bullingham R, Shah J, Goldblum R, Schiff M (1996): Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. *Br J Clin Pharmacol* 41 (6): 513-516
  14. Bullingham RE, Nicholls AJ, Kamm BR (1998): Clinical pharmacokinetics of mycophenolate mofetil. *Clin Pharmacokinet* 34 (6): 429-455
  15. Burke SK, Slatopolsky EA, Goldberg DI (1997): RenaGel<sup>®</sup>, a novel calcium- and aluminium-free phosphate binder inhibits phosphate absorption in normal volunteers. *Nephrol Dial Transplant* 12: 1640-1644
  16. Burke S, Amin N, Incerti C, Plone M, Lee JW (2001): Sevelamer hydrochloride (Renagel<sup>®</sup>), a nonabsorbed phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers. *J Clin Pharmacol* 41: 199-205
  17. Burke S, Amin N, Incerti C, Plone M, Watson N (2001): Sevelamer hydrochloride (Renagel<sup>®</sup>), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics. *J Clin Pharmacol* 41: 193-198
  18. Campana C, Regazzi MB, Buggia I (1996): Drug interactions: Clinically significant drug interactions with cyclosporine: An update. *Clin Pharmacokinet* 30: 141-179
  19. Carl S, Wiesel M And The Mycophenolate Mofetil Study Group (1997): Mycophenolate mofetil (Cellcept<sup>®</sup>) in renal transplantation: The european experience. *Transplant Proc* 29: 2932-2935
  20. Cattaneo D, Gaspari F, Ferrari S, Stucchi N, del Priore L, Perico N, Gotti E, Remuzzi G (2001): Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. *Clin Transplant* 15: 402-409
  21. Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, Bonventre JV, Slatopolsky E (1997): Polyallylamine hydrochloride (Renagel<sup>®</sup>): A

- noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. *Am J Kidney Dis* 29: 66-71
22. Chertow GM, Martin KJ (1998): Current and future therapies for the medical management of secondary hyperparathyroidism. *Seminars in Dialysis* 11: 267-270
  23. Chertow GM, Burke SK, Dillon MA, Slatopolsky E for the RenaGel Study Group (1999): Long-term effects of Sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. *Nephrol Dial Transplant* 14: 2907-2914
  24. Chertow GM, Dillon M, Burke SK, Steg M, Bleyer AJ, Garrett BN, Domoto DT, Wilkes BM, Wombolt DG, Slatopolsky E (1999): A randomized trial of sevelamer hydrochloride (RenaGel<sup>®</sup>) with and without supplemental calcium. *Clin Nephrol* 51: 18-26
  25. Chertow GM, Burke SK, Raggi P; Treat To Goal Working Group (2002): Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. *Kidney Int* 62 (1): 245-252
  26. Christians U, Sewing KF (1993): Cyclosporin metabolism in transplant patients. *Pharmacol Ther* 57 (2-3): 291-345
  27. Claesson K, Mayer AD, Squifflet J-P, Grabensee B, Eigler FW, Behrend M, Vanrenterghem Y, van Hoff J, Morales JM, Johnson RGW, Buchholz B, Land W, Forsythe JLR, Neumayer H-H, Ericzon B-G, Mühlbacher F (1998): Lipoprotein patterns in renal transplant patients: A comparison between FK 506 and cyclosporine A patients. *Transplant Proc* 30: 1292-1294
  28. Collins AJ, Peter WLSt, Dalleska FW, Ebben JP, Ma JZ (2000): Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. *Clin Nephrol* 54: 334-341
  29. Conroy S, Choonara I et al. on behalf of the European Network For Drug Investigation In Children (2000): Survey of unlicensed and off label drug use in paediatric wards in european countries. *BMJ* 320: 79-82
  30. Cooney GF, Habucky K, Hoppu K (1997): Cyclosporin pharmacokinetics in paediatric transplant recipients. *Clin Pharmacokinet* 32 (6): 481-495
  31. Copeland KR, Thliveris JA, Yatscoff RW (1990): Toxicity of cyclosporine metabolites. *Ther Drug Monit* 12: 525-532

32. Copeland KR, Yatscoff RW (1990): Immunosuppressive activity and toxicity of cyclosporine metabolites characterized by mass spectroscopy and nuclear magnetic resonance. *Transplant Proc* 22 (3): 1146-1149
33. Ducharme MP, Provenzano R, Dehoorne-Smith M (1993): Trough concentrations of cyclosporine in blood following administration with grapefruit juice. *Br J Clin Pharmacol* 36: 457-459
34. Eifinger F, Wahn F, Querfeld U, Pollok M, Gevargez A, Kriener P, Grönemeyer D (2000): Coronary artery calcifications in children and young adults treated with renal replacement therapy. *Nephrol Dial Transplant* 15: 1892-1894
35. Elder GJ (2001): Pathogenesis and management of hyperparathyroidism in end-stage renal disease and after renal transplantation. *Nephrology* 6: 155-160
36. Fahr A, Hiestand P, Ryffel B (1990): Studies on the biologic activities of Sandimmun<sup>®</sup> metabolites in humans and in animal models: Review and original experiments. *Transplant Proc* 22 (3): 1116-1124
37. Fahr A (1993): Cyclosporin clinical pharmacokinetics. *Clin Pharmacokinet* 24 (6): 472-495
38. Falkiewicz K, Kuriata M, Boratynska M, Klinger M, Szepietowski T, Patrzalek, Szyber P (2002): Mycophenolate mofetil reduces graft loss due to chronic allograft nephropathy. *Transplant Proc* 34: 567-568
39. Fernández de Gatta MdM, Santos-Buelga D, Domínguez-Gil A, García MJ (2002): Immunosuppressive therapie for paediatric transplant patients: Pharmacokinetic considerations. *Clin Pharmacokinet* 41 (2): 115-135
40. Filler G, Mai I, Filler S, Ehrich JHH (1999): Abbreviated cyclosporine AUCs on Neoral<sup>®</sup> – the search continues! *Pediatr Nephrol* 13: 98-102
41. Filler G, Zimmering M, Mai I (1999): Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. *Pediatr Nephrol* 14: 100-104
42. Filler G, Gellermann J, Zimmering M, Mai I (2000): Effect of adding mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity. *Transpl Int* 13: 201-206
43. Filler G, Mai I (2000): Limited sampling strategy for mycophenolic acid area under zhe curve. *Ther Drug Monit* 22(2): 169-173
44. Fliser G, Ritz E (1999): Störungen des Kalzium- und Phosphathaushalts. *Der Urologe [A]* 38: 285-295

45. Freeman DJ, Martell R, Carruthers SG, Heinrichs D, Keown PA, Stiller CR (1987): Cyclosporin-erythromycin interaction in normal subjects. *Br J Clin Pharmacol* 23 (6): 776-778
46. Fricker G, Drewe J, Huwylar J, Gutmann H, Beglinger C (1996): Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: In vitro-in vivo correlation. *Br J Pharmacol* 118: 1841-1847
47. Gallieni M, Cozzolino M, Brancaccio D (2000): Transient decrease of serum bicarbonate levels with sevelamer hydrochloride as the phosphate binder. *Kidney Int* 57 (4): 1776-1777
48. Goldberg DI, Dillon MA, Slatopolsky EA, Garrett B, Gray JR, Marbury T, Weinberg M, Wombolt D, Burke SK (1998): Effect of RenaGel<sup>®</sup>, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium and intact parathyroid hormone in end-stage renal disease patients. *Nephrol Dial Transplant* 13: 2303-2310
49. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000): Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. *N Engl J Med* 342: 1478-1483
50. Grimm RH, Hunninghake DB (1986): Lipids and hypertension. Implications of new guidelines for cholesterol management in the treatment of hypertension. *Am J Med* 80 (2A): 56-63
51. Guérin AP, London GM, Marchais SJ, Metivier F (2000): Arterial stiffening and vascular calcifications in end-stage renal disease. *Nephrol Dial Transplant* 15: 1014-1021
52. Guillen-Anaya M-A, Jadoul M (2004): Drug interaction between sevelamer and cyclosporin. *Nephrol Dial Transplant* 19: 515
53. Halloran PF, Helms LMH, Kung L, Noujaim J (1999): The temporal profile of calcineurin inhibition by cyclosporine in vivo. *Transplantation* 68 (9): 1356-1361
54. Helderman JH (1999): Lessons from the Neoral<sup>®</sup> global database for renal transplantation. *Transplant Proc* 31: 1659-1663
55. Hergesell O, Ritz E (1999): Phosphate binders on iron basis: A new perspective? *Kidney Int* 56 (73): S42-S45

56. Hou SH, Zhao J, Ellmann CF, Hu J, Griffin Z, Spiegel DM, Bourdeau JE (1991): Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. *Am J Kidney Dis* 18: 217-224
57. Hsu CH (1997): Are we mismanaging calcium and phosphate metabolism in renal failure? *Am J Kidney Dis* 29: 641-649
58. Hsu CY, Chertow GM (2002): Elevations of serum phosphorus and potassium in mild to moderate chronic renal insufficiency. *Nephrol Dial Transplant* 17 (8): 1419-1425
59. Jacqz-Aigrain E, Khan Shaghaghi E, Baudouin V, Popon M, Zhang D, Maisin A, Loirat C (2000): Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. *Pediatr Nephrol* 14: 95-99
60. Jensen RA, Lal SM, Diaz-Arias A, James-Kracke M, Van Stone JC, Ross G Jr. (1995): Does cholestyramine interfere with cyclosporine absorption? A prospective study in renal transplant patients. *ASAIO J* 41 (3): M704-M706
61. Johnston A, Holt DW (1999): Therapeutic drug monitoring of immunosuppressant drugs. *Br J Clin Pharmacol* 47: 339-350
62. Johnston A, David OJ, Cooney GF (2000): Pharmacokinetic validation of Neoral<sup>®</sup> absorption profiling. *Transplant Proc* 32 (Suppl 3A): 53S-56S
63. Kahan BD, Kramer WG, Wideman C, Flechner SM, Lorber MI, van Buren CT (1986): Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. *Transplantation* 41 (4): 459-464
64. Kahan BD, Shaw LM, Holt D, Grevel J, Johnston A (1990): Consensus document: Hawk's Cay Meeting on therapeutic drug monitoring of cyclosporine. *Clin Chem* 36 (8): 1510-1516
65. Kahan BD, Welsh M, Schoenberg L, Rutzky LP, Katz SM, Urbauer DL, Van Buren CT (1996): Variable oral absorption of Cyclosporine: A biopharmaceutical risk factor for chronic renal allograft rejection. *Transplantation* 62 (5): 599-606
66. Kaplan B, Meier-Kriesche HU, Friedmann G, Mulgaonkar S, Gruber S, Korecka M, Brayman KL, Shaw LM (1999): The effect of renal insufficiency on mycophenolic acid protein binding. *J Clin Pharmacol* 39: 715-720
67. Kates DM, Andress DL (1996): Control of hyperphosphatemia in renal failure: Role of aluminium. *Seminars in Dialysis* 9: 310-315

68. Kays MB, Overholser BR, Mueller BA, Moe SM, Sowinski KM (2003): Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. *Am J Kidney Dis* 42 (6): 1253-1259
69. Khachatryan N, Wauters JP, Vogel G (2002): Effekt of mycophenolate mofetil in combination with standart immunosuppression on chronic transplant nephropathy: 1 year experience. *Transplant Proc* 34: 807-808
70. Knöppel C, Klinger O, Soergel M, Seyberth HW, Leonhardt A (2000): Anwendung von Medikamenten außerhalb der Zulassung oder ohne Zulassung bei Kindern. *Monatsschr Kinderheilkd* 148: 904-908
71. Konstadinidou I, Boletis JN, Chelioti H, Avdikou K, Theodoropoulou H, Gounari P, Kostakis A, Stathakis CP (2001): The effect of Neoral<sup>®</sup> on plasma cholesterol concentration in renal transplant recipients. *Transplant Proc* 33: 2393-2394
72. Korecka M, Nikolic D, van Breemen RB, Shaw LM (1999): The apparent inhibition of inosine monophosphate dehydrogenase by mycophenolic acid glucuronide is attributable to the presence of trace quantities of mycophenolic acid. *Clin Chem* 45 (7): 1047-1050
73. Kunzendorf U, Walz G, Brockmoeller J, Neumayer H-H, Jochimsen F, Roots I, Offermann G, Strom TB (1991): Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney allograft recipients. *Transplantation* 52 (2): 280-284
74. Lindholm A, Dahlqvist R, Groth GG, Sjoqvist F (1990): A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation. *Br J Clin Pharmacol* 30 (3): 443-452
75. Lipsky JJ (1996): Mycophenolate mofetil. *Lancet* 348: 1357-1359
76. Loghman-Adam M (1999): Phosphate binders for control of phosphate retention in chronic renal failure. *Pediatr Nephrol* 13: 701-708
77. Mahalati K, Belitsky P, Kiberd B, West K, Fraser A, MacDonald AS, McAlister V, Lawen J (2000): Absorption profiling – a novel method for monitoring Neoral<sup>®</sup> in kidney transplantation that reduces rejection and nephrotoxicity. *Transplantation* 69 (8): 35-45
78. Mahdavi H, Kuizon BD, Gales B, Wang HJ, Elashoff RM, Salusky IB (2003): Sevelamer hydrochloride: An effective phosphate binder in dialyzed children. *Pediatr Nephrol* 18 (12): 1260-1264

79. Mai I, Krüger H, Budde K, Johne A, Brockmöller J, Neumayer H-H, Roots I (2000): Hazardous pharmacokinetic interaction of Saint John's wort (*hypericum perforatum*) with the immunosuppressant cyclosporin. *Int J Clin Pharmacol and Ther* 38: 500-502
80. Malluche HH, Monier-Faugere MC (1999): Understanding and managing hyperphosphatemia in patients with chronic renal disease. *Clin Nephrol* 52: 267-277
81. Milliner DS, Zinsmeister AR, Lieberman F, Landing B (1990): Soft tissue calcification in pediatric patients with end-stage renal disease. *Kidney Int* 38 (5): 931-936
82. Morii M, Ueno K, Ogawa A, Kato R, Yoshimura H, Wada K, Hashimoto H, Takada M, Tanaka K, Nakatani T, Shibakawa M (2000): Impairment of mycophenolate mofetil absorption by iron ion. *Clin Pharmacol Ther* 68 (6): 613-616
83. Mourad M, Malaise J, Eddour DC, De Meier M, König J, Schepers R, Squifflet JP, Wallemacq P (2001): Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. *Clin Chem* 47 (1): 88-94
84. Mück W, Mai I, Fritsche L, Ochmann K, Rohde G, Unger S, Johne A, Bauer S, Budde K, Roots I, Neumayer H-H, Kuhlmann J (1999): Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. *Clin Pharmacol Ther* 65: 251-261
85. Mueller EA, Kovarik JM, Kutz K (1994): Minor influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine. *Transplant Proc* 26 (5): 2957-2958
86. Nagano N, Miyata S, Obana S, Ozai M, Kobayashi N, Fukushima N, Burke SK, Wada M (2001): Sevelamer hydrochloride (Renagel<sup>®</sup>), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency. *Nephrol Dial Transplant* 16: 1870-1878
87. Neuvonen PJ, Kivistö K, Hirvisalo EL (1988): Effects of resins and activated charcoal on the absorption of digoxin, carbamazepin and frusemide. *Br J Clin Pharmacol* 25 (2): 229-233
88. Nowak I, Shaw LM (1995): Mycophenolic acid binding to human serum albumin: Characterization and relation to pharmacodynamics. *Clin Chem* 41: 1011-1017



89. Ojo AO, Meier-Kriesche H-U, Hanson JA, Leichtman AB, Cibrik D, Magee JC, Wolfe RA, Agodoa LY, Kaplan B (2000): Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. *Transplantation* 69 (11): 2405-2409
90. Pillans PI, Rigby RJ, Kubler P, Willis C, Salm P, Tett SE, Taylor PJ (2001): A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients. *Clin Biochem* 34: 77-81
91. Plone MA, Petersen JS, Rosenbaum DP, Burke SK (2002): Sevelamer, a phosphate-binding polymer, is a non-absorbed compound. *Clin Pharmacokinet* 41 (7): 517-523
92. Pohlmeier R, Vienken J (2001): Phosphate removal and hemodialysis conditions. *Kidney Int* 59 (78): 190-194
93. Portman RJ, Meier-Kriesche HU, Swinford R, Brannan P, Kahan BD (2000): Reduced variability of Neoral<sup>®</sup> pharmacokinetic studies in pediatric renal transplantation. *Pediatr Nephrol* 15: 2-6
94. Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH (2002): Effects of phosphate binders on supplemental iron absorption in healthy subjects. *J Clin Pharmacol* 42: 1171-1176
95. Ribeiro S, Ramos A, Brandão A, Rebelo JR, Guerra A, Resina C, Vila-Lobos A, Carvalho F, Remédio F, Ribeiro F (1998): Cardiac valve calcification in haemodialysis patients: Role of calcium-phosphate metabolism. *Nephrol Dial Transplant* 13: 2037-2040
96. Rosano TG, Brooks CA, Dybas MT, Cramer SM, Stevens C, Freed BM (1990): Selection of an optimal assay method for monitoring cyclosporine therapy. *Transplant Proc* 22 (3): 1125-1128
97. Rosenbaum DP, Holmes-Farley SR, Mandeville WH, Pitruzello M, Goldberg DI (1997): Effect of RenaGel<sup>®</sup>, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats. *Nephrol Dial Transplant* 12: 961-964
98. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, Watkins PB (1997): Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. *Drug Metab Dispos* 25 (11): 1228-1233
99. Schütz E, Shipkova M, Armstrong VW, Wieland E, Oellerich M (1999): Identification of a pharmacologically active metabolite of mycophenolic acid in

- plasma of transplant recipients treated with mycophenolate mofetil. *Clin Chem* 45 (3): 419-421
100. Seifeldin R (1995): Drug interactions in transplantation. *Clinical Therapeutics* 17 (6): 1043-1061
  101. Shah MB, Martin JE, Schroeder TJ, First MR (1999): The evaluation of the safety and tolerability of two formulations of cyclosporine: Neoral<sup>®</sup> and Sandimmun<sup>®</sup>: A meta-analysis. *Transplantation* 67 (11): 1411-1417
  102. Shipkova M, Schütz E, Armstrong VW, Niedmann PD, Wieland E, Oellerich M (1999): Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite. *Transplant Proc* 31 (1-2): 1135-1137
  103. Slatopolsky E (1973): The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. *Kidney Int* 4: 141-145
  104. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, MacDonald PN (1996): Phosphorus restriction prevents parathyroid gland growth. *J Clin Invest* 97 (11): 2534-2540
  105. Slatopolsky E, Dusso A, Brown AJ (1999): The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure. *Am J Med Sci* 317: 370-376
  106. Slatopolsky E, Burke SK, Dillon MA and the RenaGel<sup>®</sup> Study Group (1999): RenaGel<sup>®</sup>, a nonabsorbed calcium- and aluminium-free phosphate binder, lowers serum phosphorus and parathyroid hormone. *Kidney Int* 55: 299-307
  107. Staskewitz A, Kirste G, Tönshoff B, Weber LT, Böswald M, Burghard R, Helmchen U, Brandis M, Zimmerhackl LB (2001): Mycophenolat mofetil in pediatric renal transplantation without induction therapy: Results after 12 months of treatment. *Transplantation* 71: 638-644
  108. Steimer W (1999): Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: How specific is specific? *Clin Chem* 45 (3): 371-381
  109. Strologo LD, Campagnano P, Federici G, Rizzoni G (1999): Cyclosporine A monitoring in children: Abbreviated area under the curve formulas and c<sub>2</sub> level. *Pediatr Nephrol* 13: 95-97
  110. Sud K, Singh B, Shree Krishna V, Thennarasu K, Kohli HS, Jha V, Gupta KL, Sakhuja V (1999): Unpredictable cyclosporin-fluconazol interaction in renal transplant recipients. *Nephrol Dial Transplant* 14: 1698-1703

111. Trull AK, Tan KK, Tan L, Alexander GJ, Jamieson NV (1995): Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion. *Br J Clin Pharmacol* 39 (6): 627-631
112. Turner S, Nunn AJ, Fielding K, Choonara I (1999): Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: A prospective study. *Acta Paediatr* 88: 965-968
113. Wadhwa NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, First MR (1987): The effect of oral metoclopramide on the absorption of cyclosporine. *Transplant Proc* 19 (1): 1730-1733
114. Wallot M, Bonzel K-E, Winter A, Geörger B, Lettgen B, Bald M (1996): Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients. *Pediatr Nephrol* 10: 625-630
115. Wang EJ, Casciano CN, Clement RP, Johnson WW (2001): Inhibition of p-glycoprotein transport function by grapefruit juice Psolaren. *Pharm Res* 18 (4): 432-438
116. Weber L, Shipkova M, Lamersdorf T, Niedmann PD, Wiesel M, Mandelbaum A, Zimmerhackl LB, Schütz E, Mehls O, Oellerich M, Armstrong VW, Tönshoff B (1998): Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. *J Am Soc Nephrol* 9: 1511-1520
117. Weber LT, Schütz E, Lamersdorf T, Shipkova M, Niedmann PD, Oellerich M, Zimmerhackl LB, Staskewitz A, Mehls O, Armstrong VW, Tönshoff B and The German Study Group On Mycophenolate Mofetil Therapie (1999): Therapeutic drug monitoring of total and free mycophenolic acid (MPA) and limited sampling strategy for determination of MPA-AUC in paediatric renal transplant recipients. *Nephrol Dial Transplant* 14 (4): 34-35
118. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schütz E, Mehls O, Zimmerhackl LB, Oellerich M, Tönshoff B (2002): Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. *Clin Chem* 48 (3): 517-525
119. Wüthrich RP, Weinreich T, Ambühl PM, Schwarzkopf A-K, Candinas D, Binswanger U (1999): Reduced kidney transplant rejection rate and pharmaco-

- economic advantage of mycophenolate mofetil. Nephrol Dial Transplant 14: 394-399
120. Yamaguchi T, Baxter JG, Maebashi N, Asano T (1999): Oral phosphate binders: Phosphate binding capacity of iron (III) hydroxide complexes containing saccharides and their effect on the urinary excretion of calcium and phosphate in rats. Renal Failure 21 (5): 453-468
121. Yu DK (1999): The contribution of p-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 39: 1203-1211

### **Bücherzitate**

122. Forth W, Henschler D, Rummel W, Starke K (Hrsg): Allgemeine und spezielle Pharmakologie und Toxikologie. Wissenschaftsverlag Mannheim / Leipzig / Wien / Zürich 1996
123. Illing S, Claßen M: Klinikleitfaden Pädiatrie, Urban & Fischer 6. Auflage, Juni 2003

### **Firmenschriften**

124. Abbott: TDx<sup>®</sup> Bedienungsanleitung 82-6671 (Mai 1994): Systembeschreibung / Messtheorie. Fluoreszenzpolarisations-Immunoassay: 1-44
125. Abbott: TDx<sup>®</sup>/TDxFLx<sup>®</sup> (November 2000): Cyclosporin und Metabolite (Vollblut).
126. Genzyme B.V. (2000): Scientific discussion Renagel<sup>®</sup>.
127. Genzyme Therapeutics (1998): Produktprofil und klinische Erfahrung von Renagel<sup>®</sup>.
128. Institut für Laboratoriumsmedizin und Pathobiochemie der Charité (2001): Normwerte Klinische Chemie
129. Medical Tribune Hospital (Schweiz): Medikamentöse Interaktionen und Cytochrom P-450. Suppl. 49: 18-20
130. Microgenics<sup>™</sup>: CEDIA<sup>®</sup> Cyclosporin Plus, In Vitro Diagnostikum.
131. Syva-Company, Dade Behring Inc.: EMIT<sup>®</sup>-Mycophenolsäure-Test, In Vitro Diagnostikum.